MS Potential Therapy – This New Drug Exhibits Incredible Potential

There may be excellent news for those individuals whose daily lives are overshadowed by the disease like MS. The race is finally on to develop a more effective remedy for the disease between main drug manufactures. Merck has been in the process of testing their newest remedy Cladribine as a possible MS treatment. Their analysis has proven that sufferers who have undergone a short sequence of remedies with this new oral drug have a very high rate of success in achieving decreased relapse rates when in comparison with lots of the at the moment out there medications for MS.

To emphasize the potential for Cladribine as a remedy for MS the producer presented a report to the European Committee for Treatment and Research in Multiple Sclerosis Congress. The results they presented showed involved a study group consisting of sufferers who took one of two different doses or a placebo. The outcomes showed that 43 and 44 per cent of those taking the drug were discovered to be symptom free for a period of two full years. This was in comparison with solely 16 per cent of those who got the placebo.

Merck is at the moment working closely with the FDA to achieve approval even as their rivals at Biogen and Novartis are creating mediations and searching for approval. The overall potential for Cladribine as an MS remedy is slightly overshadowed by a really slight risk of cancer in some patients. As this may be the primary oral remedy out there for MS sufferers and as such could possibly be a possible blockbuster for the manufacturer.

One of many greatest advantages of this remedy is for those in the late stage of multiple sclerosis are far less likely to end up being disabled. It has also been proven that this new drug might help to reduce the risk of lesions developing. In accordance with many neurologists the potential for Cladribine as an MS remedy far outweighs any identified risks and in reality they are far more more likely to prescribe this new drug for their sufferers in any phase of the disease over the medicines being developed by either Novartis or Biogen.

Irrespective of which set of tests you have a look at the numbers coming back present the definite potential of Cladribine as a remedy for MS. Sufferers who have waited years for a really efficient remedy are anxiously awaiting approval of this new remedy and are praying that the FDA does not drag their feet. That is the primary new remedy to come back along in many years to show this type of potential and anticipation is high in both the medical community and sufferers alike.